TY  - THES
AB  - Phenylketonuria (PKU) is a genetic disorder caused by a deficiency of phenylalanine hydroxylase leading to decreased conversion of phenylalanine (Phe) to tyrosine (Tyr). Pegvaliase™ (Palynziq™, BioMarin Pharmaceutical Inc., Novato, CA, USA), an injectable enzyme replacement therapy decreases plasma Phe by converting Phe intro trans-cinnamic acid and ammonia. This study aims to evaluate the changes in the dietary composition of participants with PKU on pegvaliase.
AU  - Khoo, Vi V.
DA  - 2019
DO  - 10.6083/9w0323552
DO  - DOI
ID  - 7588
KW  - Dietary Proteins
KW  - Diet Therapy
KW  - therapeutic use
KW  - pegvaliase
KW  - phenylketonuria
L1  - https://digitalcollections.ohsu.edu/record/7588/files/khoo.vivien.2019.pdf
L2  - https://digitalcollections.ohsu.edu/record/7588/files/khoo.vivien.2019.pdf
L4  - https://digitalcollections.ohsu.edu/record/7588/files/khoo.vivien.2019.pdf
LK  - https://digitalcollections.ohsu.edu/record/7588/files/khoo.vivien.2019.pdf
N2  - Phenylketonuria (PKU) is a genetic disorder caused by a deficiency of phenylalanine hydroxylase leading to decreased conversion of phenylalanine (Phe) to tyrosine (Tyr). Pegvaliase™ (Palynziq™, BioMarin Pharmaceutical Inc., Novato, CA, USA), an injectable enzyme replacement therapy decreases plasma Phe by converting Phe intro trans-cinnamic acid and ammonia. This study aims to evaluate the changes in the dietary composition of participants with PKU on pegvaliase.
PB  - Oregon Health and Science University
PY  - 2019
T1  - Secondary analyses of dietary data from PRISM  clinical trials to evaluate safety and efficacy of pegvaliase for adults with PKU
TI  - Secondary analyses of dietary data from PRISM  clinical trials to evaluate safety and efficacy of pegvaliase for adults with PKU
UR  - https://digitalcollections.ohsu.edu/record/7588/files/khoo.vivien.2019.pdf
Y1  - 2019
ER  -